China National Medicines Corporation Ltd(600511)
2021 social responsibility performance report
China National Medicines Corporation Ltd(600511) (hereinafter referred to as ” China National Medicines Corporation Ltd(600511) ” or “company”) is the largest pharmaceutical and health industry group in China with the most complete industrial chain and the strongest comprehensive strength, and the first A-share listed company of China Meheco Group Co.Ltd(600056) Group Co., Ltd., one of the world’s top 500 enterprises, It is the largest distributor of drugs and healthcare products in China and a subsidiary of Sinopharm Holding Co., Ltd., a leading supply chain service provider China National Medicines Corporation Ltd(600511) formerly known as China Meheco Group Co.Ltd(600056) company, the company was established by China Meheco Group Co.Ltd(600056) Group Co., Ltd. on December 21, 1999 and was successfully listed on Shanghai Stock Exchange in 2002. In July 2006, China Meheco Group Co.Ltd(600056) Group Co., Ltd. invested 58.67% of the company’s equity in Sinopharm Holdings Co., Ltd. by way of capital increase, and Sinopharm Holdings Co., Ltd. became the controlling shareholder of the company. Through the implementation of the distribution to value-added plan in 2007 and 2008 and the completion of major asset restructuring projects in 2017, the current registered capital of the company is 754502998 yuan.
China National Medicines Corporation Ltd(600511) business scope includes: Wholesale Drugs; Organize drug production; Sales of medical devices (class II and III); Pre packaged food sales (including refrigerated and frozen food), special food sales (health food, infant formula milk powder); Internet information services do not include news, publishing, education, medical care and electronic announcement services, including drugs and medical devices; Information services in the second category of value-added telecommunications services (excluding fixed network telephone information services and Internet information services); Sales of medical devices (class I), daily necessities, cosmetics, automobiles (excluding passenger cars with less than nine seats), electronic products, computer software and auxiliary equipment, household appliances, sanitary products, electromechanical equipment, mechanical equipment and accessories; Import and export business; Consultation related to the above business; Conference services; Technical services; Technology development; Computer system services; Mechanical equipment leasing; Formula food for special medical purposes. Disinfection supplies.
2021 is an extraordinary year for China National Medicines Corporation Ltd(600511) . Under the correct leadership of the group, state control, the board of directors and the Party committee of the company, the company prudently and smoothly completed the overlapping work of the Secretary of the Party committee, the Secretary of the Discipline Inspection Commission, the leader in charge of operation and the chief financial officer. Standing at the historical intersection of “two centenaries”, the company overcame the impact of policies, epidemics and other aspects, The “14th five year plan” was launched with head held high, and all tasks of operation and management were well completed. 1、 Based on the main business, promote the sustainable development of the company
China National Medicines Corporation Ltd(600511) has 13 holding subsidiaries, forming an intensive business model integrating commerce, logistics, industry and international trade. At the same time, the company’s foreign equity investment has also achieved good returns.
With the joint efforts of all staff in 2021, China National Medicines Corporation Ltd(600511) achieved good business performance, achieved effective implementation and achieved tangible business results under the requirements of high-quality development of Sinopharm group and Sinopharm holdings. In the whole year, the operating income (excluding tax) was 46.469 billion yuan, the net profit attributable to the shareholders of the parent company was 1.754 billion yuan, and the tax was 1.309 billion yuan. The business performance declined slightly, and continued to maintain a strong profitability in the industry, making due contributions to economic and social development. By the end of December 2021, the total assets of the company were 27.475 billion yuan and the total market value of shares was 23.789 billion yuan.
(I) adhere to dividend distribution and repay shareholders
China National Medicines Corporation Ltd(600511) has always attached importance to giving back to shareholders and society. The newly revised articles of association in 2012 stipulates that, except for special circumstances, the distributable profits of the parent company realized by the company in the current year are positive and the accumulated undistributed profits of the company at the end of the current year are positive, On the premise that the audit institution issues a standard unqualified audit report on the financial report of the current year and ensures the normal operation and long-term development of the company, in principle, cash dividends shall be paid once a year. The annual cash distribution proportion shall not be less than 10% of the distributable profits of the parent company in the current year, and the accumulated profits distributed by the company in cash for three consecutive years shall not be less than 30% of the annual distributable profits realized in the last three years.
According to the resolution of the company’s 2020 annual general meeting of shareholders, in June 2021, the company distributed cash dividends of RMB 0.55 per share (including tax) to all shareholders based on the total share capital of 754502998 shares as of December 31, 2020, with a total of 41487664890 yuan, providing continuous and good returns for shareholders. (II) pay attention to the needs of customers and keep close relationship with customers
China National Medicines Corporation Ltd(600511) deeply layout the national regional network, closely follow the relevant policies of the national pharmaceutical industry, focus on the main business status and develop characteristic businesses, and promote the improvement of market share; Closely grasp the demand dynamics of market subjects, pay attention to the special needs of customers, and continuously improve customer satisfaction.
——Hospital direct sales: the company always takes the construction of hospital net sales network as the top priority, adheres to customer demand-oriented, provides systematic, professional, fast and high-quality services for all customers, establishes a stable and good relationship with customers, and drives the rapid development of net sales business. At present, the coverage rate of the company in level II and above hospitals in Beijing has reached 100%, and the coverage rate of level I hospitals, communities and clinics has reached more than 85%.
——Sales of narcotic drugs: the national distribution business of narcotic drugs and class I psychotropic drugs is one of the most important core businesses of the company. As the most historic national wholesale enterprise dealing in narcotic drugs in China approved by the State Food and drug administration, the company has always been responsible for the central reserve and national allocation of narcotic drugs and class I psychotropic drugs. The company operates a full range of narcotic drugs and class I psychotropic drugs listed in China. The sales network of narcotic drugs covers more than 600 regional wholesale enterprises of narcotic drugs in 31 provinces, municipalities directly under the central government and autonomous regions, and provides special drugs supply and related services to more than 60000 medical institutions across the country.
(III) operate in compliance with laws and regulations and continue to operate in a standardized manner
The company takes legal and compliant operation and continuous standardized operation as the concept to continuously improve law-abiding and compliance work. In terms of organization, the company has established legal compliance department, audit department, party masses work department and risk and operation management department to carry out the company’s law-abiding and compliance work with reasonable division of labor and cooperation; In terms of system and process construction, the company has established and improved the law-abiding and compliance management system and corresponding work processes of listed company governance system, quality management system, operation and risk management system, legal management system, anti-corruption and anti commercial bribery system, forming the company’s law-abiding and compliance system, Ensure the law-abiding and compliant operation of the company’s operation and management in terms of system.
The company reduces the risk of violation of laws and regulations by strengthening the legal review of rules and regulations, major decisions, contracts and other foreign economic acts; Reduce the risk of violation in the company’s operation by strengthening operation management and risk management; Strengthen the supervision of violations of laws and disciplines by strengthening internal and external audit and discipline inspection; By strengthening the training of legal knowledge and compliance knowledge, especially the knowledge related to anti-corruption and commercial bribery, improve the compliance awareness of all employees and build the company’s compliance culture.
Through the above activities, the company’s compliance system operates well and the company’s compliance operation has made continuous progress, which is mainly reflected in: in recent years, the company has no major violations of laws and regulations, and the company’s business system operates well; Employees have enhanced legal awareness and can engage in various businesses under the provisions of national laws and regulations and the company’s system and process; The company and its employees basically put an end to violations of laws and disciplines.
(IV) the company won the following honors during the reporting period
1. China National Medicines Corporation Ltd(600511) won the 12th Tianma Award for investor relations of Chinese Listed Companies in securities times “best board of directors award of main board”;
2. China National Medicines Corporation Ltd(600511) won the best board of directors of the 17th golden round table of Chinese listed companies selected by board of directors magazine;
3. China National Medicines Corporation Ltd(600511) won the excellent prize of biomedical track of the 10th “golden wisdom Award” of leading China in the financial sector; 2、 Work on promoting sustainable social development
(I) earnestly safeguard the rights and interests of employees
The company strictly abides by the labor contract law of the people’s Republic of China, the company law, the trade union law and relevant laws and regulations, standardizes labor relations, strengthens occupational health management according to law, and provides protective measures required by posts. Follow and safeguard international human rights and labor standards signed by the Chinese government. Eliminate child labor, forced labor, employment discrimination and occupational discrimination. The principle of open, fair and impartial recruitment helps employees plan their life and career, protect the rights and interests of retired employees, and support employees to participate in social welfare activities.
1. Total number of employees: 3005
Number of female employees: 1328
Proportion of female managers (female: male): 4:6
2. Labor contract signing rate: 100%; The social insurance coverage rate of the company is 100%, and all employees pay social insurance in full according to the entry time of each person.
3. Employee career development channel: in order to standardize and unify the company’s talent selection and appointment standards, improve talent management system and process, expand employee promotion space and lay the foundation for talent echelon construction. According to the management measures for employee promotion, the company provides employees with two development channels: professional sequence and management sequence. According to the selection and employment standard of both ability and political integrity, the company will promote the potential employees with outstanding ability, excellent performance and qualified qualification after passing the examination. It enables employees to develop and grow continuously in the company, enhances personnel stability and improves the cohesion of the company.
4. Employment ratio of persons with disabilities: 0; Number of ethnic minority employees: 173
5. Physical examination rate and health file coverage rate of employees:
The company will arrange annual physical examination for all employees from August to December every year. In order to facilitate the selection of employees of the Department, the human resources department provides multiple medical examination institutions. Employees can go to the physical examination at the specified time. The physical examination report is uniformly received by the company and placed in the archives for archiving. Timely pay attention to the physical examination results of drug users of the company to ensure that the physical examination results of drug users meet the requirements 100%. The physical examination rate of non drug dependent personnel is basically 100%, except that individual employees cannot participate in the physical examination due to personal physical reasons. The coverage rate of health records reached 100%.
6. Proportion and frequency of occupational diseases: 0
7. Based on the development status and the strategic framework of human resource management, the company standardizes China National Medicines Corporation Ltd(600511) salary management in accordance with the principle of “adapting to the market environment, reflecting the value of talents and giving play to the incentive role”. With the incentive salary distribution system as the core, establish a salary system that takes into account internal fairness and market competitiveness, strive to achieve the goal of “consistency between responsibility and interest, ability and value, performance and income” in salary distribution, effectively combine personal income with China National Medicines Corporation Ltd(600511) benefits, and give full play to the incentive and health care role of salary.
China National Medicines Corporation Ltd(600511) the principles of setting welfare programs and standards for employees are risk guarantee, material incentive, cost utilization, legitimacy and fairness. The employee welfare setting system is divided into three parts: statutory welfare, caring welfare and incentive welfare. Each part includes several items and standards. Welfare programs set up to encourage employees to work hard to complete tasks and achieve excellent work performance include transportation subsidies, communication subsidies, commercial supplementary insurance and enterprise annuity.
8. Annual paid leave days per employee: the actual paid leave days per employee are about 5.1 days per capita.
9. In 2021, the company had two industrial accidents (personal commuting traffic accidents).
10. Employee training management system:
In 2021, according to the annual training plan, a total of 80 training projects were carried out, with 12340 participants. The total training hours were 71608, the training cost was 513984 yuan, and the employee training coverage rate was 100%. At the beginning of the year, the annual training demand survey was carried out, and the 2021 annual training plan was formulated to fully consider the talent demand of the enterprise’s development goals, analyze the existing working ability and target gap of employees, determine the training personnel and training contents, improve the skill level of employees, and meet the talent demand of the enterprise’s development; At the same time, we will continue to deepen the integrated training process of China National Medicines Corporation Ltd(600511) and its subsidiaries on the premise of taking into account the inclusion of various types of training into the plan.
Adhere to the principle that the party is in charge of cadres, talents and coordination between the party and the government. Under the unified leadership of the China National Medicines Corporation Ltd(600511) Party committee, refine the management division of cadre education and training: the Party committee line focuses on the party’s basic theory education and party spirit education, and mainly issues and implements the education and training requirements directly through the Party committee line and relevant departments; The human resources line focuses on improving the professional ability of cadres and broadening their knowledge. Through the combination of internal and external, Wuxi Online Offline Communication Information Technology Co.Ltd(300959) make full use of training resources, level by level and line by line, and actively promote the effective implementation of cadre education and training.
Actively explore training ways, improve training methods, arrange training contents in combination with the actual work, pay attention to the effectiveness of training, and adopt a variety of ways to flexibly guide and learn all-round knowledge China National Medicines Corporation Ltd(600511) adhere to the combination of “invite in” and “go out”, implement “menu” learning selection, and invite influential experts, professors and scholars in various fields to carry out special training, so as to seamlessly connect the ability and quality of cadres with their professional fields, such as the “practical marketing skills training of pharmaceutical enterprises under DRG and dip payment reform” carried out in February 2021. Secondly, China National Medicines Corporation Ltd(600511) actively selects new middle-level leaders to participate in the external training “core backbone manager training camp” to Improve Cadres’ self-management and team management ability and promote the overall performance of the enterprise; Participate in the special training held by Dalian Senior Management College, SASAC education and training center and other institutions, and promote the leaders to further enhance the “four awareness”, strengthen the “four self-confidence” and achieve the “two maintenance” through theme education and learning training.
Comprehensively adopt the combined training method of “offline learning + online learning”, give full play to the advantages of e-learning platform, pay close attention to the online learning platform of e-school, Sinopharm University and SASAC cadre education and training website, guide the cadres to adhere to learning all kinds of theoretical and business knowledge, form a good learning atmosphere within the company and create an all-round learning organization, The special study of “learning party history and remembering the original heart” in July 2021 and “digital special network training” in August 2021. Through continuous innovation and enrichment of training methods, we will strive to improve the pertinence and effectiveness of training, and strive to cultivate a high-quality professional cadre team that meets the needs of the strategic development of the 14th five year plan.
Assist in organizing, planning and carrying out the induction training for new employees with the theme of “passion, high efficiency and responsibility, create, share and share” in 2021. This training was conducted synchronously by means of webcast for the first time. 74 new colleagues in Beijing participated in the training on site and 34 new colleagues outside Beijing participated in the training in the way of webcast; On this basis, strengthen the training of young talents of the company, so that new employees can quickly change their roles and grow up
